ESC: Peto Analysis Called Short on Proof of Simvastatin/ Ezetimibe Cancer Safety
SEATTLE -- Simvastatin/ezetimibe (Vytorin) may increase the risk of cancer after all, concluded a leading American biostatistician who dismissed as prematurely reassuring an analysis by Richard Peto, Ph.D., F.R.S., that found the link with excess malignancy to be overblown.
Sep 04, 2008